Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06992713 | A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 36 | Shenzhen Hepalink Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07208773 | A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 260 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07656116 | Platform Study of VSV-Based Recombinant Oncolytic Viruses for the Treatment of Advanced Malignant Tumors | recruiting | Phase 1 | 27 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06636435 | A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer | recruiting | Phase 1 | 66 | Chiome Bioscience Inc.INDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07653035 | The Effect of Using Weighted Blanket on Anxiety, Stress, Depression and Comfort Level Among Patients With Cancer Undergoing Intravenous Anticancer Therapy and Its Feasibility of Use by Nurses Compared to Routine Care(CALM-WB) | recruiting | N/A | 152 | Sultan Qaboos Comprehensive Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03514368 | Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy(MINER) | recruiting | N/A | 770 | Institut Claudius RegaudOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06297525 | Study of STP938 (Dencatistat) in Advanced Solid Tumours | recruiting | Phase 1 | 70 | Step Pharma, SASINDUSTRY | 3 | Jun 16, 2026 | clinicaltrials |
| NCT05768932 | BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 260 | SillaJen, Inc.INDUSTRY | 2 | Jun 15, 2026 | clinicaltrials |
| NCT06253130 | A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 156 | Eikon TherapeuticsINDUSTRY | 8 | Jun 15, 2026 | clinicaltrials |
| NCT07019779 | Study of CM518D1 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 434 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07147348 | A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 375 | BioNTech SEINDUSTRY | 2 | Jun 15, 2026 | clinicaltrials |
| NCT07638371 | FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers | recruiting | Phase 1 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07648472 | A Study of the Safety and Efficacy of the Intravenous and Intratumoral Injection of OVV-01 in Patients With Advanced Solid Tumours. | recruiting | Phase 1 | 18 | Joint Biosciences Ltd.INDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT00991094 | Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy | recruiting | — | 5,000 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06630416 | Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors | recruiting | Phase 2 | 64 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07284186 | First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 155 | Plexium, Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07348653 | A Study of MG2512 Injection in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 116 | Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07405086 | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study | recruiting | Phase 4 | 160 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04771520 | Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05076760 | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | recruiting | Phase 1 | 40 | Memgen, Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06401356 | An Extension Study for Patients Previously Enrolled in Studies With Pelabresib | recruiting | Phase 3 | 50 | Novartis PharmaceuticalsINDUSTRY | 5 | Jun 11, 2026 | clinicaltrials |
| NCT06789172 | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors(INVOKE) | recruiting | Phase 1 | 146 | EpkinINDUSTRY | 3 | Jun 11, 2026 | clinicaltrials |
| NCT07163325 | EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors | recruiting | Phase 1 | 48 | Epics TherapeuticsINDUSTRY | 4 | Jun 11, 2026 | clinicaltrials |
| NCT04243720 | Immune Resistance Interrogation Study(IRIS) | recruiting | — | 100 | University Health Network, TorontoOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05403177 | Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)(MOHCCN-O) | recruiting | — | 500 | University Health Network, TorontoOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05521984 | Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) | recruiting | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06501040 | Increasing Knowledge and Interest in Cancer Clinical Trials | recruiting | N/A | 384 | Hayley ThompsonOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06788886 | Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases | recruiting | N/A | 147 | Mayo ClinicOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06835569 | A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | recruiting | Phase 1 | 448 | Alterome Therapeutics, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06975410 | Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors | recruiting | Phase 1 / Phase 2 | 80 | Yuhan CorporationINDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | recruiting | Phase 1 | 40 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07639047 | An Initial Evaluation of AN8025 in Solid Tumors | recruiting | Phase 1 | 91 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT04665388 | LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers(LANDMARC) | recruiting | — | 105 | University Health Network, TorontoOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05530759 | Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal | recruiting | — | 50 | Mayo ClinicOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06015932 | Group Cognitive Behavior Sessions (CBCSM) to Decrease Distress in Cancer Patients | recruiting | N/A | 400 | Mayo ClinicOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06314672 | Outreach Project to Connect Underrepresented Populations to Clinical Trials at Ohio State University, CUSP2CT Project Trial | recruiting | N/A | 208 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07137312 | Ex Vivo Expansion (ACT-X) | recruiting | — | 24 | Mayo ClinicOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT04890613 | Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation | recruiting | Phase 1 | 52 | Senhwa Biosciences, Inc.INDUSTRY | 2 | Jun 8, 2026 | clinicaltrials |
| NCT07238075 | ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers | recruiting | Phase 1 | 290 | Adcytherix SASINDUSTRY | 2 | Jun 8, 2026 | clinicaltrials |
| NCT07252479 | Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations | recruiting | Phase 1 | 118 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07512583 | Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 178 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07570563 | Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors. | recruiting | Phase 1 / Phase 2 | 24 | Chinese PLA General HospitalOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05232409 | Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer | recruiting | Phase 1 | 72 | Valley Health SystemOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06504732 | To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer | recruiting | Phase 2 / Phase 3 | 574 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06554795 | First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 360 | DualityBio Inc.INDUSTRY | 3 | Jun 5, 2026 | clinicaltrials |
| NCT06894745 | PET [89Zr]DFO-starPEG in Solid Tumors | recruiting | Phase 1 | 13 | Robert Flavell, MD, PhDOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04621435 | Imaging of Solid Tumors Using FAP-2286 | recruiting | Phase 1 | 191 | Thomas HopeOTHER | 1 | Jun 4, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 18, 2026source: clinicaltrials